| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Association between continuity of care and emergency department visits and hospitalization in senior adults with asthma-COPD overlap
|
Kao, Yu-Hsiang
|
|
2019
|
123 |
2 |
p. 222-228
|
artikel
|
| 2 |
Coordinating primary care services: A case of policy layering
|
Rudoler, David
|
|
2019
|
123 |
2 |
p. 215-221
|
artikel
|
| 3 |
Editorial Board
|
|
|
2019
|
123 |
2 |
p. ii
|
artikel
|
| 4 |
Enabling health technology innovation in Canada: Barriers and facilitators in policy and regulatory processes
|
MacNeil, Maggie
|
|
2019
|
123 |
2 |
p. 203-214
|
artikel
|
| 5 |
Health differentials between citizens and immigrants in Europe: A heterogeneous convergence
|
Bousmah, Marwân-al-Qays
|
|
2019
|
123 |
2 |
p. 235-243
|
artikel
|
| 6 |
Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients
|
Efthymiadou, Olina
|
|
2019
|
123 |
2 |
p. 159-165
|
artikel
|
| 7 |
Health technology assessment at age 25—Squaring the circle of strong methodology and context-dependency?
|
Panteli, Dimitra
|
|
2019
|
123 |
2 |
p. 115-117
|
artikel
|
| 8 |
HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey
|
García-Mochón, Leticia
|
|
2019
|
123 |
2 |
p. 182-190
|
artikel
|
| 9 |
HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries
|
Nicod, Elena
|
|
2019
|
123 |
2 |
p. 140-151
|
artikel
|
| 10 |
Questioning the differences between general public vs. patient based preferences towards EQ-5D-5L defined hypothetical health states
|
Ogorevc, Marko
|
|
2019
|
123 |
2 |
p. 166-172
|
artikel
|
| 11 |
Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease—A five-year follow-up study
|
Cheng, Hao-Min
|
|
2019
|
123 |
2 |
p. 229-234
|
artikel
|
| 12 |
Testing a new taxonomic model for the assessment of medical devices: Is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe
|
Fuchs, Sabine
|
|
2019
|
123 |
2 |
p. 173-181
|
artikel
|
| 13 |
Thanks to Reviewers 2018
|
|
|
2019
|
123 |
2 |
p. 244-247
|
artikel
|
| 14 |
Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland
|
Wranik, Wiesława Dominika
|
|
2019
|
123 |
2 |
p. 191-202
|
artikel
|
| 15 |
Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?
|
López-Bastida, J.
|
|
2019
|
123 |
2 |
p. 152-158
|
artikel
|
| 16 |
Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries
|
Visintin, Erica
|
|
2019
|
123 |
2 |
p. 118-129
|
artikel
|
| 17 |
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries
|
Maynou, Laia
|
|
2019
|
123 |
2 |
p. 130-139
|
artikel
|
Tijdschrift beschrijving